FIELD: biotechnology.
SUBSTANCE: group of inventions relates to biotechnology, particularly to siRNA and its use for treating pulmonary fibrosis and pulmonary cancer. siRNA has full length of 17-23 nucleotides and is targeted at sequence containing 17-23 consecutive bases, selected from a group consisting of bases in positions from 1,285 to 1,318, bases in positions from 1,398 to 1418, bases in positions from 1,434 to 1,463, bases in positions from 1,548 to 1,579, bases in positions from 1,608 to 1,628 , bases in positions from 1,700 to 1,726, bases in positions from 1,778 to 1,798, bases in positions from 1,806 to 1,826 and bases in positions from 1,887 to 1,907 sequence SEQ ID NO: 1.
EFFECT: for use in effective inhibition and suppression of expression of gene TGF-β1, in hybridisation.
21 cl, 5 dwg, 10 tbl, 9 ex
| Title |
Year |
Author |
Number |
| AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDES AND COMPOSITIONS CONTAINING THEM FOR THE PREVENTION AND TREATMENT OF FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES |
2019 |
- Kim, Tae-Rim
- Yoon, Pyoung Oh
- Ko, Youngho
- Bae, Seon Joo
- Park, Han-Oh
- Son, Seung Seob
- Jun-Hong, Park
- Yun, Sung Il
|
RU2795179C2 |
| GEN-SPECIFIC SIRNA RELATED TO RESPIRATORY DISEASE, TWO-SPIRAL CONSTRUCT OF OLIGO-RNA COMPRISING SIRNA, AND CONTAINING IT COMPOSITION FOR PREVENTION OR TREATMENT OF RESPIRATORY DISEASE |
2014 |
- Chkhe Chejuk
- Pak Khan O
- Yun Pen O
- Khan Boram
- Kim Mi Na
|
RU2656154C2 |
| DOUBLE-CHAINED OLIGONUCLEOTIDE SPECIFIC TO CTGF GENE AND COMPOSITION CONTAINING IT FOR PREVENTION AND TREATMENT OF FIBROUS DISEASES AND DISEASES ASSOCIATED WITH RESPIRATORY SYSTEM |
2020 |
- Park, Han-Oh
- Kim, Tae-Rim
- Ko, Young-Ho
- Yun, Sung Il
- Park, Jun Hong
|
RU2807108C1 |
| SINGLE-STRANDED CIRCULAR RNA AND METHOD FOR PRODUCING IT |
2008 |
- Abe Khirosi
- Ito Josikhiro
- Abe Naoko
- Tojobuku Khidekazu
|
RU2523596C2 |
| GENE INVOLVED IN IMMORTALISATION OF HUMAN CANCER CELL AND USE THEREOF |
2007 |
- Nisijama Masakhiko
- Khijama Kejko
- Tanimoto Kejdzi
- Masuko Norio
|
RU2449016C2 |
| TREATMENT OF DISEASES, ASSOCIATED WITH HEPATOCYTE GROWTH FACTOR (HGF), BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO HGF |
2010 |
- Kollard Dzhozef
- Khorkova Sherman Olga
|
RU2609631C2 |
| NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, METHOD OF PRODUCTION AND USE |
2020 |
- Chzhan, Khunyan
- Gao, Shan
- Kan, Dajvu
- Tyan, Baolej
|
RU2819689C2 |
| INHIBITORS OF SIGNAL TRANSMISSION OF TRANSFORMING GROWTH FACTORS (TGF-R) FOR TREATMENT OF CNS DISORDERS |
2005 |
- Bogdan Ul'Rikh
- Ajgner Ljudvig
- Vaks Frank Peter
- Vinner Beate
- Vinkler Jjurgen
|
RU2385933C2 |
| TREATMENT OF PYRROLINE-5-CARBOXYLATE REDUCTASE 1 (PYCR1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO PYCR1 |
2011 |
- Kollard Dzhozef
- Khorkova Sherman Olga
|
RU2608496C2 |
| DRUG CONTAINING mTOR INHIBITOR FOR TREATMENT OR PREVENTION OF EYE SYMPTOMS, DISORDERS, OR DISEASES, AND ITS USE |
2018 |
- Koizumi Noriko
- Okumura Naoki
|
RU2782613C2 |
